[CLSTR]
< Back to all clusters
[HEALTH] · United States · 17 sources

started · updated

Part of situation: ES-SCLC combination therapy clinical trial results (2 clusters)

Amgen and AstraZeneca drug combo reduces lung cancer death risk by 58%

Imdelltra Imfinzi small cell lung cancer Amgen AstraZeneca

Results from the Phase 3 DeLLphi-305 clinical trial show that combining Amgen’s Imdelltra (tarlatamab) with AstraZeneca’s Imfinzi (durvalumab) significantly improves outcomes for patients with extensive-stage small cell lung cancer (ES-SCLC).

The combination therapy reduced the risk of death by 58% compared to Imfinzi alone. Median overall survival for the combination group reached 21.1 months, whereas the group receiving only Imfinzi had a median survival of 12.7 months. Additionally, the one-year survival rate for the combination group was approximately 79% to 80%, compared to 53% for the control group.

Data presented at the ESMO 2026 Congress in Madrid and published in the New England Journal of Medicine indicated that severe (Grade 3 and 4) treatment-related adverse events occurred in 20.9% of the combination group. Approximately 49.6% of patients receiving Imdelltra reported cytokine release syndrome, though researchers noted these effects are manageable and only one case was reported as serious.

Entities

Amgen · AstraZeneca · Dana-Farber Cancer Institute · ESMO 2026 Congress · European Society for Medical Oncology · Imdelltra · Imfinzi

Claims

What the coverage asserts, and how many sources carry each claim.

Sources

Amgen'in Imdelltra Kombinasyonu Küçük Hücreli Akciğer Kanserinde Ölüm Riskini Yüzde 58 Azalttı [dijitaliyidir.com]
Kansere karşı dikkat çeken sonuç: Yeni yöntem ölüm riskini yüzde 60'a yakın azalttı [www.cnbce.com]
Cancro al polmone aggressivo, combinazione farmaci riduce del 58% rischio morte [notiziedi.it]
Cancro al polmone aggressivo, combinazione farmaci riduce del 58% rischio morte [www.cinquecolonne.it]
Cancro al polmone aggressivo, combinazione farmaci riduce del 58% rischio morte [www.corcianonline.it]
Cancro al polmone aggressivo, combinazione farmaci riduce del 58% rischio morte [www.espressione24.it]
Cancro polmone, con nuova combinazione malattia sotto controllo più a lungo [mantovauno.it]
Cancro al polmone aggressivo, combinazione farmaci riduce del 58% rischio morte [quotidianodifoggia.it]
Cancro al polmone aggressivo, combinazione farmaci riduce del 58% rischio morte [www.sardegnalive.net]
Cancro polmone, con nuova combinazione malattia sotto controllo più a lungo [www.vetrinatv.it]
Amgen ve AstraZeneca kombinasyonu ölüm riskini yüzde 58 azalttı [www.haber.com]
Cancro al polmone aggressivo, combinazione farmaci riduce del 58% rischio morte [www.lsdmagazine.com]
This drug combo cuts death-risk in cancer cases by 58% [www.newsbytesapp.com]
Cancro al polmone aggressivo, combinazione farmaci riduce del 58% rischio morte - Il Quotidiano del Sud [www.quotidianodelsud.it]
Cancro al polmone aggressivo, combinazione farmaci riduce del 58% rischio morte [quotidianodibari.it]
Cancro al polmone aggressivo, combinazione farmaci riduce del 58% rischio morte [www.senzalinea.it]
Cancro al polmone aggressivo, combinazione farmaci riduce del 58% rischio morte [www.trapanisi.it]